BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20870432)

  • 21. Intensity-modulated radiotherapy of the prostate after cryotherapy: initial experience.
    Hepel JT; MacAusland SG; Long JP; Wazer DE; DiPetrillo T
    Urology; 2008 Dec; 72(6):1310-4; discussion 1314. PubMed ID: 18502482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
    Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
    Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
    Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
    Aaronson DS; Yamasaki I; Gottschalk A; Speight J; Hsu IC; Pickett B; Roach M; Shinohara K
    BJU Int; 2009 Sep; 104(5):600-4. PubMed ID: 19245439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
    MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
    Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer.
    deVere White RW; Hackman RM; Soares SE; Beckett LA; Li Y; Sun B
    Urology; 2004 Feb; 63(2):259-63. PubMed ID: 14972467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Skene's Glands Adenocarcinoma: A Series of 4 Cases.
    Tregnago AC; Epstein JI
    Am J Surg Pathol; 2018 Nov; 42(11):1513-1521. PubMed ID: 29901570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastasizing adenocarcinoma of the female prostate (Skene's paraurethral glands). Histological and immunohistochemical prostate markers studies and first ultrastructural observation.
    Sloboda J; Zaviacic M; Jakubovský J; Hammar E; Johnsen J
    Pathol Res Pract; 1998; 194(2):129-36. PubMed ID: 9584326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer.
    Ingenito AC; Ennis RD; Hsu IC; Begg MD; Benson MC; Schiff PB
    Urology; 1997 Jul; 50(1):73-8. PubMed ID: 9218022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors.
    D'Amico AV; Schultz D; Schneider L; Hurwitz M; Kantoff PW; Richie JP
    J Urol; 2000 Jun; 163(6):1797-801. PubMed ID: 10799185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer.
    Pollack A; Zagars GK; Kopplin S
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):13-20. PubMed ID: 7536720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?
    Zagars GK; Kavadi VS; Pollack A; von Eschenbach AC; Sands ME
    Int J Radiat Oncol Biol Phys; 1995 Apr; 32(1):21-32. PubMed ID: 7536722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    D'Ambrosio DJ; Ruth K; Horwitz EM; Chen DY; Pollack A; Buyyounouski MK
    Urology; 2008 May; 71(5):938-41. PubMed ID: 18279939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.